RecruitingNCT06610201

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

Velora Discover: A Prospective, Screening Study of Bleeding and Treatment in Participants With Von Willebrand Disease

Sponsor

Hemab ApS

Enrollment

200 participants

Start Date

Aug 30, 2024

Study Type

OBSERVATIONAL

Conditions

Von Willebrand Disease (vWD)Von Willebrand Disease (VWD), Type 2 Von Willebrand Disease (VWD), Type 1 Von Willebrand Disease (VWD), Type 3 Von Willebrand Disease, Type 2A Von Willebrand Disease, Type 2M Von Willebrand Disease, Type 2N

Summary

The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.(e.g. Velora Pioneer)

Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Clinical outcomes of patients with VWD, Type 1 and Clinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3 for people with von willebrand disease (vwd), type 1, von willebrand disease (vwd), type 2, and other related conditions. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 16 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERClinical outcomes of patients with VWD, Type 1

Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 1

OTHERClinical outcomes of patients with VWD, Type 2A, Type 2M, Type 2N, or Type 3

Accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeding events in participants with VWD, Type 2A, Type 2M, Type 2N and Type 3.

Locations(17)

Phoenix Children's Hospital

Phoenix, Arizona, United States

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Children's Hospital of Los Angeles

Los Angeles, California, United States

University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center

Miami, Florida, United States

Emory Children's Center

Atlanta, Georgia, United States

Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center

Indianapolis, Indiana, United States

Tulane University School of Medicine

New Orleans, Louisiana, United States

University of Michigan Hospitals, Department of Hemophilia and Coagulation Disorders

Ann Arbor, Michigan, United States

Mayo Clinic - Rochester

Rochester, Minnesota, United States

Oregon Health & Science University

Portland, Oregon, United States

Hemophilia Center of Western Pennsylvania

Pittsburgh, Pennsylvania, United States

The University of Texas Southwestern Medical Center

Dallas, Texas, United States

Washington Institute For Coagulation (WIC)

Seattle, Washington, United States

Fiona Stanley Hospital

Murdoch, Perth, Australia

Royal Prince Alfred Hospital

Camperdown, Sydney, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Richmond Pharmacology

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06610201

Related Trials

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

NCT0675485225 locations

A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease

NCT076408939 locations

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

NCT0558299321 locations

Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease

NCT0665125517 locations

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

NCT0711500414 locations